For example, in tumors with higher spectrum of somatic mutational burdens, such as melanoma and non–small cell lung cancers, treatment with anti–PD-1 blockade has resulted in significantly improved survival outcome [14,32,33]. Here, PDCD1 is linked to melanoma.